BioNTech SE (BNTX)
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating.
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Daina Graybosch - Leerink Partners Suzanne van Voorthuizen - VLK Terence Flynn - Morgan Stanley Yaron Werber - TD Cowen Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Luke Shumway - BMO Capital Markets Ellie Merle - UBS Yifeng Liu - HSBC Bank Plc Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Jay Olson - Oppenheimer Operator Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
BioNTech surprises with Q3 profit driven by strong vaccine sales
BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-based company also posted sales of €1.2 billion, nearly three times higher than anticipated.
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
BioNTech's Oncology Gamble: High Stakes, Big Potential
BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution.
BioNTech (BNTX) Presents at Innovation Series: AI Day
BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, InstaDeep Youssef Ben Dhieb - Senior ML Engineer, InstaDeep Thomas Pierrot - Research Scientist, InstaDeep Maren Lang - Senior Director, Bioinformatics R&D, BioNTech Marie Lopez - Research Engineer Team Lead, InstaDeep Daniel Rothenberg - Associate Director, Proteomics, BioNTech Michael Rooney - Director, Computational Biology, BioNTech Nicolas Lopez Carranza - Head of BioAI, InstaDeep Hippolyte Jacomet - Research Engineer, InstaDeep Sven Coutandin - Director, Global R&D Automation, BioNTech David Drakard - Senior Research Engineer, InstaDeep Michael Dahms - Director, Digitization R&D Labs, BioNTech Conference Call Participants Sam Fazeli - Bloomberg Intelligence Harry - Time Magazine Ian Johnston - Financial Times Unidentified Speaker - Karim Beguir Hi everyone. Welcome to AI Day.
BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
